| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
|
J Clin Oncol
|
2007
|
3.99
|
|
2
|
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112).
|
Blood
|
2004
|
2.17
|
|
3
|
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
|
Leuk Res
|
2011
|
1.50
|
|
4
|
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.
|
Blood
|
2006
|
1.38
|
|
5
|
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.
|
J Immunol
|
2005
|
1.26
|
|
6
|
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
|
Blood
|
2011
|
1.19
|
|
7
|
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.
|
Blood
|
2002
|
1.02
|
|
8
|
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
|
PLoS One
|
2011
|
1.00
|
|
9
|
Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
|
J Antimicrob Chemother
|
2004
|
0.97
|
|
10
|
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
|
Leuk Lymphoma
|
2011
|
0.91
|
|
11
|
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
|
Eur J Haematol
|
2008
|
0.91
|
|
12
|
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.
|
PLoS One
|
2011
|
0.90
|
|
13
|
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
|
Leuk Lymphoma
|
2010
|
0.89
|
|
14
|
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
|
Haematologica
|
2010
|
0.85
|
|
15
|
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.
|
Haematologica
|
2013
|
0.85
|
|
16
|
APO866 activity in hematologic malignancies: a preclinical in vitro study.
|
Blood
|
2009
|
0.85
|
|
17
|
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
|
Br J Haematol
|
2007
|
0.82
|
|
18
|
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.
|
Br J Haematol
|
2007
|
0.81
|
|
19
|
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
|
Leuk Lymphoma
|
2012
|
0.81
|
|
20
|
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
|
Ann Hematol
|
2009
|
0.80
|
|
21
|
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
|
Leuk Res
|
2011
|
0.79
|
|
22
|
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
|
Ann Hematol
|
2004
|
0.79
|
|
23
|
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
|
Am J Hematol
|
2014
|
0.78
|
|
24
|
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.
|
Leuk Lymphoma
|
2006
|
0.78
|
|
25
|
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
|
Oncol Rep
|
2005
|
0.77
|
|
26
|
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
|
Br J Haematol
|
2007
|
0.77
|
|
27
|
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
28
|
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.
|
Oncol Rep
|
2009
|
0.75
|